GUTTA » Újdonságok

The new issue of the Elesta newsletter “EchoLaser News”


Dear Doctor,


We are pleased to share the new issue of the Elesta newsletter “EchoLaser News”, which aims to offer periodic information on the main activities of the Company and beyond.


Thanks to the experience of hundreds of users of the EchoLaser system, with this initiative we intend, in fact, to collect and relaunch the news and information that in the health and health services landscape refer to the inspiring concepts of the action of Elesta: the activities of research, monitoring, evaluation, training and innovation.


We are convinced that quality, efficiency and fairness are decisive elements in the organization of health care and being able to have up-to-date information on good practices carried out in this direction is a useful tool for both decision makers and operators.


You can also find and download EchoLaser News editions on our Corporate website.

The Hologic 3D Mammography™ exam: Now FDA approved superior for women with dense breasts!



To further differentiate the Hologic 3D Mammography ™ exam from competitive tomosynthesis exams, we are thrilled to share some ground-breaking new claims that only we can deliver.  You should understand these claims and start to use them to differentiate Hologic.


Powerful New Density Labelling

The U.S. Food and Drug Administration (FDA) recently approved new labeling that allows us to make the following, compelling claim:

This claim is important due to the fact that between 40 and 50 percent of women ages 40-74 have dense breasts, which complicates imaging, making it difficult to detect lesions, and increases the risk of breast cancer by 4-5 times .2, 3

Only Hologic, and facilities with Hologic 3D Mammography™ equipment, get these results and can make these claims.



Stronger Invasive Cancer Claim

The updated invasive cancer detection claim now contains a range with a higher upper end which states that:

Only Hologic, and facilities with Hologic 3D Mammography™ capable equipment get these results and can make these claims.

The range represents the results a facility can expect with the 3D Mammography™ exam with an upper limit of 65% making it even more impactful than our prior claim of 41% which is still the average.


“Effect of Age” Study

This new study, “Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography,” led by Elizabeth Rafferty, MD and based on subgroup data analysis from the 2014 JAMA study, looked at the performance of tomosynthesis in specific age groups. The study showed that:

Only Hologic, and facilities with Hologic 3D Mammography™ equipment get these results and can make these claims.


1 Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.
2 Ho JM, Jafferjee N, Covarrubias GM, Ghesani M, Handler B. Dense breasts: a review of reporting legislation and available supplemental screening options. AJR Am J Roentgenol. 203(2):449-56, 2014.
3 Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. 106(10), 2014.
4 Results from Friedewald, SM, et al. “Breast cancer screening using tomosynthesis in combination with digital mammography.” JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions® system on screening outcomes. Individual results may vary.  The study found that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic® 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
FDA submissions P080003, P080003/S001, P080003/S005
Zuckerman SP, Conant EF, Keller BM, et al. Implementation of Synthesized Two-dimensional Mammography in a Population-based Digital Breast Tomosynthesis Screening Program. Radiology. 2016 Dec;281(3):730-736
Skaane P, Bandos A, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology. 2014 Jun;271(3):655-63.
Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncol. 2016 Jun 1;2(6):737-43.
10 Rafferty EA, Durand MA, Conant EF, et al.Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA. 2016 Apr 26;315(16):1784-6.
11 Rafferty E, Rose S, Miller D, et al. Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography. Breast Cancer Research and Treatment – Clinical Trial – DOI 10.1007/s10549-017-4299-0.

A kontraszt mammográfia alapelvei




Már néhány tudományos tanulmány bizonyította, hogy a mammográfia csökkenti a mellrákban való elhalálozást. A mammográfia sikeressége a rák identifikálásának képességétől függ a röntgensugarak különböző abszorpciója alapján a rákos szövetekben a szír és mirigyes szövetekhez képest.


I-View szoftver – A kontraszt mammográfia alapelvei


A kontraszt mammográfia a rák felismerésére volt kifejlesztve, amit gyakran a hagyományos mammográfiai vizsgálatkor nem lehet látni. A kontraszt mammográfiás kivizsgálás a mammográfia vagy ultrahang után következik, hogy az érdeklődési területről részletesebb információkhoz jussanak.


Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 


— Study Demonstrates Benefits of Testing 30-65 Year-Old Women for Cervical Cancer with Both Pap and HPV Tests —